Liminal BioSciences Ltd.
10
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
50.0%
5 terminated/withdrawn out of 10 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
Role: lead
A Healthy Volunteer Study of PBI-4050
Role: lead
Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects
Role: lead
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
Role: lead
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
Role: lead
Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Role: lead
Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Role: lead
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Role: lead
Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
Role: lead
Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
Role: lead
All 10 trials loaded